MNKD
MannkindยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MNKD Profile
Mannkind Corporation
A company that develops innovative therapeutic products for endocrine and orphan lung diseases
Biological Technology
02/14/1991
07/28/2004
NASDAQ Stock Exchange
403
12-31
Common stock
1 Casper Street, Danbury, Connecticut 06810
--
Mannkind Corporation was incorporated in Delaware on February 14, 1991. Mannkind Corporation is a biopharmaceutical company focused on the development, development and promotion of therapies and drugs such as diabetes and cancer. The company's lead product candidate, AFREZZA Inhalation Powder, is a super fast-acting insulin in late-stage clinical research for the control and treatment of hyperglycemia in adults with type 1 or type 2 diabetes. AFREZZA is loaded into insulin molecules by the company's proprietary technology circle particles. After nebulized inhalation, these loaded particles penetrate deep into the lungs using the AFREZZA inhaler. Diabetes is a major health problem.
